Alopecia areata trials in China

In China 9 Also abroad 44

9 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Where
Beijing, Shanghai, Tianjin
Age
18 years to 60 years
People
65 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07533006 · EU 2025-524727-41-00
Phase 3Taking people
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
Where
Beijing, Shanghai
Age
12 years and over
People
336 worldwide
Run by
Pfizer
See details and how to joinNCT07733765
Phase 3Taking people
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Where
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang, Nanjing, Shanghai
Age
12 years and over
People
674 worldwide
Run by
Pfizer
See details and how to joinNCT06873945 · EU 2024-519370-40-00
Phase 1Taking people
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata
Where
Beijing
Age
12 years to 18 years
People
24
Run by
Jiangsu vcare pharmaceutical technology co., LTD
See details and how to joinNCT07762443
Phase 3Taking people
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Where
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Shenzhen, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an
Age
12 years to 63 years
People
1,500 worldwide
Run by
AbbVie
See details and how to joinNCT06012240 · EU 2023-505061-82-01
Phase 3Taking people
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Where
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Shanghai
Age
6 years to 14 years
People
140 worldwide
Run by
Pfizer
See details and how to joinNCT07029828 · EU 2024-515439-31-00
Phase 2Taking people
Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata
Where
Beijing
Age
18 years to 65 years
People
120
Run by
Jiangsu vcare pharmaceutical technology co., LTD
See details and how to joinNCT07749716
Phase 1Taking people
Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
Where
Shanghai
Age
18 years to 80 years
People
160
Run by
Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07554222
No phaseTaking people
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
Where
Hangzhou
Age
2 years to 80 years
People
150
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06573593